DK2255826T3 - Neisserial vaccine compositions comprising a combination of antigens. - Google Patents
Neisserial vaccine compositions comprising a combination of antigens. Download PDFInfo
- Publication number
- DK2255826T3 DK2255826T3 DK10177890.0T DK10177890T DK2255826T3 DK 2255826 T3 DK2255826 T3 DK 2255826T3 DK 10177890 T DK10177890 T DK 10177890T DK 2255826 T3 DK2255826 T3 DK 2255826T3
- Authority
- DK
- Denmark
- Prior art keywords
- protein
- outer membrane
- antigens
- strain
- hsf
- Prior art date
Links
- 108091007433 antigens Proteins 0.000 title claims description 138
- 102000036639 antigens Human genes 0.000 title claims description 138
- 239000000427 antigen Substances 0.000 title claims description 131
- 239000000203 mixture Substances 0.000 title claims description 123
- 229960005486 vaccine Drugs 0.000 title claims description 99
- 241001212279 Neisseriales Species 0.000 title description 54
- 108090000623 proteins and genes Proteins 0.000 claims description 201
- 102000004169 proteins and genes Human genes 0.000 claims description 133
- 238000000034 method Methods 0.000 claims description 94
- 238000002360 preparation method Methods 0.000 claims description 89
- 239000012528 membrane Substances 0.000 claims description 86
- 241000040340 Oat mosaic virus Species 0.000 claims description 78
- 230000014509 gene expression Effects 0.000 claims description 71
- 230000002163 immunogen Effects 0.000 claims description 69
- 150000004676 glycans Chemical class 0.000 claims description 60
- 229920001282 polysaccharide Polymers 0.000 claims description 58
- 239000005017 polysaccharide Substances 0.000 claims description 58
- 241000588650 Neisseria meningitidis Species 0.000 claims description 57
- 208000015181 infectious disease Diseases 0.000 claims description 32
- 241000588653 Neisseria Species 0.000 claims description 30
- 230000001105 regulatory effect Effects 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 25
- 241000894006 Bacteria Species 0.000 claims description 24
- 101710116435 Outer membrane protein Proteins 0.000 claims description 20
- 239000002671 adjuvant Substances 0.000 claims description 19
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 claims description 18
- 150000002482 oligosaccharides Chemical class 0.000 claims description 17
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 229920001542 oligosaccharide Polymers 0.000 claims description 14
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 101100241886 Neisseria meningitidis oatWY gene Proteins 0.000 claims description 11
- 108091033319 polynucleotide Proteins 0.000 claims description 11
- 102000040430 polynucleotide Human genes 0.000 claims description 11
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 229910052727 yttrium Inorganic materials 0.000 claims description 9
- 101100203230 Neisseria meningitidis serogroup B (strain MC58) siaA gene Proteins 0.000 claims description 8
- 101100021843 Shigella flexneri lpxM1 gene Proteins 0.000 claims description 8
- 101100021844 Shigella flexneri lpxM2 gene Proteins 0.000 claims description 8
- 101150060640 lpxM gene Proteins 0.000 claims description 8
- 101150019075 neuA gene Proteins 0.000 claims description 8
- 101100451792 Bacillus subtilis (strain 168) htrB gene Proteins 0.000 claims description 7
- 101150011311 lpxL gene Proteins 0.000 claims description 7
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 6
- 229940024545 aluminum hydroxide Drugs 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 101710186862 Factor H binding protein Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 101150057501 synA gene Proteins 0.000 claims description 4
- 101100329455 Cereibacter sphaeroides (strain ATCC 17023 / DSM 158 / JCM 6121 / CCUG 31486 / LMG 2827 / NBRC 12203 / NCIMB 8253 / ATH 2.4.1.) crtC gene Proteins 0.000 claims description 3
- 101150059761 ctrA gene Proteins 0.000 claims description 3
- 101150056963 ctrB gene Proteins 0.000 claims description 3
- 101150117300 ctrC gene Proteins 0.000 claims description 3
- 101150055828 ctrD gene Proteins 0.000 claims description 3
- 101150054232 pyrG gene Proteins 0.000 claims description 3
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims description 2
- 208000002352 blister Diseases 0.000 description 124
- 235000018102 proteins Nutrition 0.000 description 115
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 80
- 108010031133 Transferrin-Binding Protein A Proteins 0.000 description 74
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 67
- 239000002158 endotoxin Substances 0.000 description 56
- 108020004414 DNA Proteins 0.000 description 53
- 229920006008 lipopolysaccharide Polymers 0.000 description 53
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 42
- 230000000844 anti-bacterial effect Effects 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 38
- 239000012634 fragment Substances 0.000 description 34
- 229910052742 iron Inorganic materials 0.000 description 33
- 239000013615 primer Substances 0.000 description 33
- 230000001681 protective effect Effects 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 30
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 30
- 101150093941 PORA gene Proteins 0.000 description 27
- 229940009976 deoxycholate Drugs 0.000 description 27
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 27
- 238000003556 assay Methods 0.000 description 26
- 230000003827 upregulation Effects 0.000 description 26
- 101100168130 Danio rerio copb1 gene Proteins 0.000 description 24
- 101150026524 hap gene Proteins 0.000 description 24
- 230000008569 process Effects 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 21
- 230000028993 immune response Effects 0.000 description 20
- 230000021615 conjugation Effects 0.000 description 19
- 230000003828 downregulation Effects 0.000 description 19
- 230000035772 mutation Effects 0.000 description 19
- 239000002609 medium Substances 0.000 description 18
- 241000588724 Escherichia coli Species 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 230000004224 protection Effects 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- 238000002255 vaccination Methods 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 16
- 230000037430 deletion Effects 0.000 description 16
- 238000012217 deletion Methods 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 108010031127 Transferrin-Binding Protein B Proteins 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 101000874355 Escherichia coli (strain K12) Outer membrane protein assembly factor BamA Proteins 0.000 description 13
- 108010073429 Type V Secretion Systems Proteins 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 230000000890 antigenic effect Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 241000606768 Haemophilus influenzae Species 0.000 description 11
- -1 Sulfo-NHS ester Chemical class 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 206010018612 Gonorrhoea Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000003053 toxin Substances 0.000 description 10
- 231100000765 toxin Toxicity 0.000 description 10
- 108700012359 toxins Proteins 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 229940047650 haemophilus influenzae Drugs 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 231100000252 nontoxic Toxicity 0.000 description 8
- 230000003000 nontoxic effect Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 101150032923 tbpA gene Proteins 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 241000193998 Streptococcus pneumoniae Species 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000001784 detoxification Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 208000001786 gonorrhea Diseases 0.000 description 7
- 230000006801 homologous recombination Effects 0.000 description 7
- 238000002744 homologous recombination Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 101150095079 menB gene Proteins 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101100259999 Neisseria meningitidis serogroup B (strain MC58) tbp1 gene Proteins 0.000 description 6
- 101710183389 Pneumolysin Proteins 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- IDDIJAWJANBQLJ-UHFFFAOYSA-N desferrioxamine B mesylate Chemical compound [H+].CS([O-])(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN IDDIJAWJANBQLJ-UHFFFAOYSA-N 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 101150095556 tbpB gene Proteins 0.000 description 6
- 101150084216 thiB gene Proteins 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- AZXKALLRCOCGBV-UHFFFAOYSA-N 1-phenyl-2-(propan-2-ylamino)hexan-1-one Chemical compound CCCCC(NC(C)C)C(=O)C1=CC=CC=C1 AZXKALLRCOCGBV-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 101000873843 Homo sapiens Sorting and assembly machinery component 50 homolog Proteins 0.000 description 5
- 241000588655 Moraxella catarrhalis Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 102100035853 Sorting and assembly machinery component 50 homolog Human genes 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 229940099217 desferal Drugs 0.000 description 5
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 229940125575 vaccine candidate Drugs 0.000 description 5
- 230000001018 virulence Effects 0.000 description 5
- 208000031729 Bacteremia Diseases 0.000 description 4
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 101710085938 Matrix protein Proteins 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 101710127721 Membrane protein Proteins 0.000 description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 201000005702 Pertussis Diseases 0.000 description 4
- 108010093965 Polymyxin B Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 229960003983 diphtheria toxoid Drugs 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002480 immunoprotective effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 229920000024 polymyxin B Polymers 0.000 description 4
- 229960005266 polymyxin b Drugs 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229960000814 tetanus toxoid Drugs 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 101100120080 Arabidopsis thaliana FHA2 gene Proteins 0.000 description 3
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 101150036540 Copb1 gene Proteins 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 101100245206 Dictyostelium discoideum psmC4 gene Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 3
- 101150022636 MAFB gene Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 241000897304 Neisseria meningitidis H44/76 Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 description 3
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000001268 conjugating effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000002222 downregulating effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 3
- 230000000521 hyperimmunizing effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 208000037909 invasive meningococcal disease Diseases 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 208000037941 meningococcal disease Diseases 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 108020005029 5' Flanking Region Proteins 0.000 description 2
- CNNSWSHYGANWBM-UHFFFAOYSA-N 6-chloro-2,3-dimethylquinoxaline Chemical compound C1=C(Cl)C=C2N=C(C)C(C)=NC2=C1 CNNSWSHYGANWBM-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101100483656 Escherichia coli (strain K12) ugd gene Proteins 0.000 description 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 2
- 101710088566 Flagellar hook-associated protein 2 Proteins 0.000 description 2
- 108010084884 GDP-mannose transporter Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101100406392 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) omp26 gene Proteins 0.000 description 2
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 description 2
- 101150100310 Hsf gene Proteins 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 102100034408 Nuclear transcription factor Y subunit alpha Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000011795 OF1 mouse Methods 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101710188053 Protein D Proteins 0.000 description 2
- 101710110023 Putative adhesin Proteins 0.000 description 2
- 101710132893 Resolvase Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 101100155269 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) udg gene Proteins 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 102100021119 Serine protease HTRA1 Human genes 0.000 description 2
- 241000862632 Soja Species 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 108091053403 TonB-dependent receptor family Proteins 0.000 description 2
- 244000000188 Vaccinium ovalifolium Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 229940001007 aluminium phosphate Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 159000000013 aluminium salts Chemical class 0.000 description 2
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 2
- 238000010976 amide bond formation reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 101150008162 arnC gene Proteins 0.000 description 2
- 101150099720 basR gene Proteins 0.000 description 2
- 101150037285 basS gene Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000004643 cyanate ester Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- PZZHMLOHNYWKIK-UHFFFAOYSA-N eddha Chemical compound C=1C=CC=C(O)C=1C(C(=O)O)NCCNC(C(O)=O)C1=CC=CC=C1O PZZHMLOHNYWKIK-UHFFFAOYSA-N 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011544 gradient gel Substances 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 229940124731 meningococcal vaccine Drugs 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 101150047779 ompB gene Proteins 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 101150069659 pmrA gene Proteins 0.000 description 2
- 101150012896 pmrB gene Proteins 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 101150031507 porB gene Proteins 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000009021 pre-vaccination Methods 0.000 description 2
- 101150043772 psmC3 gene Proteins 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 101150101156 slc51a gene Proteins 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000005737 synergistic response Effects 0.000 description 2
- 101150101515 tbpl2 gene Proteins 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- ALEBYBVYXQTORU-UHFFFAOYSA-N 6-hydrazinyl-6-oxohexanoic acid Chemical compound NNC(=O)CCCCC(O)=O ALEBYBVYXQTORU-UHFFFAOYSA-N 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- TXCIAUNLDRJGJZ-BILDWYJOSA-N CMP-N-acetyl-beta-neuraminic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@]1(C(O)=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-BILDWYJOSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- NLDWTJBJFVWBDQ-KKUMJFAQSA-N Cys-Lys-Phe Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 NLDWTJBJFVWBDQ-KKUMJFAQSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 108010000916 Fimbriae Proteins Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 101000812705 Gallus gallus Endoplasmin Proteins 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- AIJAPFVDBFYNKN-WHFBIAKZSA-N Gly-Asn-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN)C(=O)N AIJAPFVDBFYNKN-WHFBIAKZSA-N 0.000 description 1
- FUTAPPOITCCWTH-WHFBIAKZSA-N Gly-Asp-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O FUTAPPOITCCWTH-WHFBIAKZSA-N 0.000 description 1
- 101710123608 HSF-like protein Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- KPYAOIVPJKPIOU-KKUMJFAQSA-N Leu-Lys-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O KPYAOIVPJKPIOU-KKUMJFAQSA-N 0.000 description 1
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 1
- 208000034762 Meningococcal Infections Diseases 0.000 description 1
- 101100017567 Mycoplasma gallisepticum (strain R(low / passage 15 / clone 2)) hlp1 gene Proteins 0.000 description 1
- 101100395360 Mycoplasma gallisepticum (strain R(low / passage 15 / clone 2)) hlp3 gene Proteins 0.000 description 1
- QVLMCRFQGHWOPM-ZKWNWVNESA-N N-arachidonoyl vanillylamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCC1=CC=C(O)C(OC)=C1 QVLMCRFQGHWOPM-ZKWNWVNESA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010062212 Neisseria infection Diseases 0.000 description 1
- 101001121800 Neisseria meningitidis Polysialic acid O-acetyltransferase Proteins 0.000 description 1
- 241000921898 Neisseria meningitidis serogroup A Species 0.000 description 1
- 241000947238 Neisseria meningitidis serogroup C Species 0.000 description 1
- 241001573069 Neisseria meningitidis serogroup Y Species 0.000 description 1
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 101100525628 Picea mariana SB62 gene Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100035181 Plastin-1 Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 102000010912 Transferrin-Binding Proteins Human genes 0.000 description 1
- 206010054824 Tubo-ovarian abscess Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000025845 adhesion to host Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000001948 anti-meningococcal effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 108091016312 choline binding proteins Proteins 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960001425 deferoxamine mesylate Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007893 endotoxin activity Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 102000036073 hemoglobin binding proteins Human genes 0.000 description 1
- 108091010989 hemoglobin binding proteins Proteins 0.000 description 1
- SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 101150051207 hmw3 gene Proteins 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 description 1
- 229940062780 lacto-n-neotetraose Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 229940014135 meningitis vaccine Drugs 0.000 description 1
- 229960005037 meningococcal vaccines Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 230000003571 opsonizing effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 108010049148 plastin Proteins 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- WQVJHHACXVLGBL-GOVYWFKWSA-N polymyxin B1 Polymers N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)CCCC[C@H](C)CC)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 WQVJHHACXVLGBL-GOVYWFKWSA-N 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
- A61K39/1045—Moraxella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0218036A GB0218036D0 (en) | 2002-08-02 | 2002-08-02 | Vaccine |
| GB0218037A GB0218037D0 (en) | 2002-08-02 | 2002-08-02 | Vaccine composition |
| GB0218051A GB0218051D0 (en) | 2002-08-02 | 2002-08-02 | Vaccine composition |
| GB0218035A GB0218035D0 (en) | 2002-08-02 | 2002-08-02 | Vaccine composition |
| GBGB0220197.8A GB0220197D0 (en) | 2002-08-30 | 2002-08-30 | Refolding method |
| GBGB0220199.4A GB0220199D0 (en) | 2002-08-30 | 2002-08-30 | Mutant protein and refolding method |
| GB0225524A GB0225524D0 (en) | 2002-11-01 | 2002-11-01 | Vaccine composition |
| GB0225531A GB0225531D0 (en) | 2002-11-01 | 2002-11-01 | Vaccine |
| GB0230168A GB0230168D0 (en) | 2002-12-24 | 2002-12-24 | Vaccine composition |
| GB0230164A GB0230164D0 (en) | 2002-12-24 | 2002-12-24 | Vaccine composition |
| GB0230170A GB0230170D0 (en) | 2002-12-24 | 2002-12-24 | Vaccine |
| GB0305028A GB0305028D0 (en) | 2003-03-05 | 2003-03-05 | Vaccine |
| EP03784153A EP1524993B1 (en) | 2002-08-02 | 2003-07-31 | Neisserial vaccine compositions comprising a combination of antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2255826T3 true DK2255826T3 (en) | 2016-06-20 |
Family
ID=31722002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10177890.0T DK2255826T3 (en) | 2002-08-02 | 2003-07-31 | Neisserial vaccine compositions comprising a combination of antigens. |
| DK03784153.3T DK1524993T3 (da) | 2002-08-02 | 2003-07-31 | Neisseria-vaccinesammensætning omfattende en kombination af antigener |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03784153.3T DK1524993T3 (da) | 2002-08-02 | 2003-07-31 | Neisseria-vaccinesammensætning omfattende en kombination af antigener |
Country Status (25)
| Country | Link |
|---|---|
| US (9) | US20060240045A1 (enExample) |
| EP (11) | EP2481419A3 (enExample) |
| JP (7) | JP2006500963A (enExample) |
| KR (6) | KR101237329B1 (enExample) |
| CN (2) | CN1671413A (enExample) |
| AU (6) | AU2003260357B2 (enExample) |
| CA (4) | CA2493977A1 (enExample) |
| CO (3) | CO5680456A2 (enExample) |
| CY (3) | CY1114243T1 (enExample) |
| DE (2) | DE20321889U1 (enExample) |
| DK (2) | DK2255826T3 (enExample) |
| ES (3) | ES2537737T3 (enExample) |
| HU (1) | HUE029200T2 (enExample) |
| IL (3) | IL165660A0 (enExample) |
| IS (3) | IS7593A (enExample) |
| LU (1) | LU92262I2 (enExample) |
| MX (3) | MXPA05001349A (enExample) |
| MY (1) | MY149591A (enExample) |
| NO (3) | NO20050010L (enExample) |
| NZ (4) | NZ574530A (enExample) |
| PL (5) | PL375408A1 (enExample) |
| PT (2) | PT1524993E (enExample) |
| SI (2) | SI1524993T1 (enExample) |
| TW (1) | TWI360424B (enExample) |
| WO (4) | WO2004015099A2 (enExample) |
Families Citing this family (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2261341A3 (en) | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| US10967045B2 (en) * | 1998-11-02 | 2021-04-06 | Secretary of State for Health and Social Care | Multicomponent meningococcal vaccine |
| GB9823978D0 (en) * | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
| EP1228217B1 (en) | 1999-04-30 | 2012-11-21 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
| EP1860191A3 (en) | 1999-05-19 | 2008-02-13 | Novartis Vaccines and Diagnostics S.r.l. | Combination neisserial compositions |
| GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| EP2275552B1 (en) | 1999-10-29 | 2015-09-09 | GlaxoSmithKline Biologicals SA | Neisserial antigenic peptides |
| GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
| IL150822A0 (en) * | 2000-01-25 | 2003-02-12 | Univ Queensland | PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA |
| CN101139590B (zh) | 2000-02-28 | 2012-07-18 | 启龙股份公司 | 奈瑟球菌蛋白质的杂交表达 |
| ES2519440T3 (es) | 2000-07-27 | 2014-11-07 | Children's Hospital & Research Center At Oakland | Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| MXPA04000653A (es) | 2001-07-27 | 2004-11-22 | Chiron Srl | Adhesinas de meningococcus nada, app y orf 40. |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| DK2255826T3 (en) * | 2002-08-02 | 2016-06-20 | Glaxosmithkline Biologicals Sa | Neisserial vaccine compositions comprising a combination of antigens. |
| GB0220194D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| DE60335477D1 (de) * | 2002-10-11 | 2011-02-03 | Novartis Vaccines & Diagnostic | Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| BRPI0414267A (pt) | 2003-09-19 | 2006-11-21 | Epitopix Llc | polipeptìdeos de campilobacter e métodos de uso |
| ATE506963T1 (de) | 2003-10-02 | 2011-05-15 | Novartis Vaccines & Diagnostic | Kombinationsimpfstoffe gegen meningitis |
| GB0323709D0 (en) * | 2003-10-09 | 2003-11-12 | Health Prot Agency | Modified whole cell,cell extract and omv-based vaccines |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US7628995B2 (en) * | 2003-12-23 | 2009-12-08 | Glaxosmithkline Biologicals S.A. | Outer membrane vesicles and uses thereof |
| GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| CN1997392B (zh) * | 2004-05-11 | 2011-06-01 | 荷兰健康、福利与体育部部长代表的荷兰国 | 作为佐剂的脑膜炎奈瑟氏菌lgtB LOS |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| GB0419408D0 (en) * | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
| GB0419627D0 (en) | 2004-09-03 | 2004-10-06 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| HUE026826T2 (en) | 2004-10-29 | 2016-07-28 | Ratiopharm Gmbh | Modeling and glycopegylation of fibroblast growth factor (FGF) |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| GB0428381D0 (en) * | 2004-12-24 | 2005-02-02 | Isis Innovation | Vaccine |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| AU2006206234B2 (en) | 2005-01-21 | 2012-01-12 | Epitopix, Llc | Yersinia spp. polypeptides and methods of use |
| DK2682126T3 (en) | 2005-01-27 | 2017-02-27 | Children's Hospital & Res Center At Oakland | GNA1870-based vesicle vaccines for broad-spectrum protection against diseases caused by Neisseria meningitidis |
| EP1871795A4 (en) | 2005-04-08 | 2010-03-31 | Biogenerix Ag | COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE |
| PL2878307T3 (pl) | 2005-06-27 | 2020-01-31 | Glaxosmithkline Biologicals S.A. | Kompozycja immunogenna |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US7955817B2 (en) | 2005-09-02 | 2011-06-07 | Glaxosmithkline Biologicals S.A. | Vaccine protection assay |
| EP1922546B1 (en) | 2005-09-05 | 2010-10-20 | GlaxoSmithKline Biologicals S.A. | Serum bactericidal assay for n. meningitidis specific antisera |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| EP1962902A2 (en) * | 2005-12-06 | 2008-09-03 | Universita Degli Studi di Padova | Methods and compositions relating to adhesins as adjuvants |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| PL3017827T3 (pl) | 2005-12-22 | 2019-04-30 | Glaxosmithkline Biologicals Sa | Szczepionka z koniugatem polisacharydu pneumokokowego |
| CU23549A1 (es) * | 2005-12-29 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Composiciones farmacéuticas que contienen la proteína nma0939 |
| KR101541383B1 (ko) | 2006-03-30 | 2015-08-03 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
| US20090246224A1 (en) * | 2006-06-12 | 2009-10-01 | Nathalie Devos | Vaccine |
| US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| CN103357003A (zh) | 2006-09-07 | 2013-10-23 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗 |
| JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー／エス | ポリペプチドコンジュゲートの精製方法 |
| GB0700136D0 (en) | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| RS52845B (sr) | 2007-04-03 | 2013-12-31 | Biogenerix Ag | Postupci tretmana korišćenjem glikopegiliranog g-csf |
| JP5876649B2 (ja) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | ヌクレオチド糖の改良製造法 |
| US9610339B2 (en) | 2007-06-26 | 2017-04-04 | Glaxosmithkline Biologicals, S.A. | Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates |
| CA2695467A1 (en) * | 2007-08-02 | 2009-03-26 | Children's Hospital & Research Center At Oakland | Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| BRPI0814793A2 (pt) * | 2007-08-02 | 2015-02-03 | Glaxosmithkline Biolog Sa | Método de tipagem molecular los de uma cepa neisseria, kit, e, método de diagnóstico e classificação de uma colonização de neisseria e/ou infecção em um hospedeiro susceptível à colonização de neisseria. |
| NZ584683A (en) | 2007-10-19 | 2012-05-25 | Novartis Ag | Neisseria meningitidis serogroup B vaccine formulations |
| US9579372B2 (en) | 2008-02-21 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Meningococcal fHBP polypeptides |
| ES2476690T3 (es) | 2008-02-27 | 2014-07-15 | Novo Nordisk A/S | Moléculas conjugadas del Factor VIII |
| PL2268618T3 (pl) | 2008-03-03 | 2015-11-30 | Novartis Ag | Związki i kompozycje jako modulatory aktywności receptorów TLR |
| US9387239B2 (en) * | 2008-05-30 | 2016-07-12 | U.S. Army Medical Research And Materiel Command | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
| KR101042541B1 (ko) * | 2008-07-25 | 2011-06-17 | 한국생명공학연구원 | 외막소체를 생산하는 재조합 ｇ（－） 박테리아 및 이를이용한 다가항원이 실린 외막소체의 제조방법 |
| WO2010027729A2 (en) * | 2008-08-25 | 2010-03-11 | Creatv Microtech, Inc. | Gonococcal vaccines |
| GB0816447D0 (en) | 2008-09-08 | 2008-10-15 | Glaxosmithkline Biolog Sa | Vaccine |
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| BRPI0923006A2 (pt) | 2008-12-17 | 2016-03-08 | Novartis Ag | vacinas meningococicas incluindo receptor de hemoglobina |
| CN101759781B (zh) * | 2008-12-25 | 2013-04-03 | 上海市第六人民医院 | 一种细菌表层黏附蛋白及其用途 |
| US8647634B2 (en) | 2008-12-25 | 2014-02-11 | The Chemo-Sero-Therapeutic Research Institute | Recombinant avian infectious coryza vaccine and process for preparing same |
| EP2208787A1 (en) * | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| ES2797504T3 (es) | 2009-03-24 | 2020-12-02 | Glaxosmithkline Biologicals Sa | Proteína de enlace del factor H meningocócico utilizada como adyuvante |
| BRPI1009829A2 (pt) | 2009-03-24 | 2016-11-16 | Novartis Ag | combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos |
| NZ595223A (en) * | 2009-03-24 | 2013-12-20 | Novartis Ag | Combinations including pneumococcal serotype 14 saccharide |
| EP2429576A1 (fr) * | 2009-05-14 | 2012-03-21 | Sanofi Pasteur | Vaccin meningocoque a base de lipooligosaccharide (los) et de proteine de neisseria meningitidis |
| WO2010130898A2 (fr) | 2009-05-14 | 2010-11-18 | Sanofi Pasteur | Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6 |
| EP2429658B1 (fr) | 2009-05-14 | 2016-04-20 | Sanofi Pasteur | Procédé pour adjuver le lipopolysaccharide (LPS) des bactéries à gram-négatif |
| WO2010134225A1 (ja) * | 2009-05-20 | 2010-11-25 | 国立大学法人鳥取大学 | 部分糖鎖エピトープを用いた、病原性ナイセリア属細菌感染の検出方法およびそれら細菌に対するワクチン |
| CN102762226A (zh) | 2009-06-10 | 2012-10-31 | 诺华有限公司 | 含苯并萘啶的疫苗 |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| CN102740882A (zh) | 2009-08-27 | 2012-10-17 | 诺华有限公司 | 含有铝、寡核苷酸和聚阳离子的佐剂 |
| BR112012004275A2 (pt) | 2009-08-27 | 2016-11-16 | Novartis Ag | polipeptídios híbridos incluindo sequências meningocócicas de fhbp |
| WO2011027956A2 (ko) | 2009-09-04 | 2011-03-10 | 주식회사이언메딕스 | 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델 |
| WO2011027971A2 (ko) | 2009-09-01 | 2011-03-10 | 주식회사이언메딕스 | 장내 공생 세균유래 세포밖 소포체, 및 이를 이용한 질병모델, 백신, 후보 약물 탐색 방법, 및 진단 방법 |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
| GB0917002D0 (en) * | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
| WO2011039631A2 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
| EP2493499A1 (en) | 2009-10-27 | 2012-09-05 | Novartis AG | Modified meningococcal fhbp polypeptides |
| WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
| AU2010315115B2 (en) * | 2009-11-06 | 2015-01-29 | Children's Hospital & Research Center At Oakland | T-cell stimulating protein B and methods of use |
| US9408907B2 (en) | 2009-12-15 | 2016-08-09 | Glaxosmithkline Biologicals Sa | Homogenous suspension of immunopotentiating compounds and uses thereof |
| JP2013521326A (ja) * | 2010-03-10 | 2013-06-10 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| ES2663872T3 (es) * | 2010-03-11 | 2018-04-17 | Glaxosmithkline Biologicals S.A. | Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria |
| WO2012020326A1 (en) | 2010-03-18 | 2012-02-16 | Novartis Ag | Adjuvanted vaccines for serogroup b meningococcus |
| JP5848748B2 (ja) | 2010-03-23 | 2016-01-27 | アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ | 感染症、炎症、呼吸器疾患などの処置に使用するｔｌｒ２アゴニストとしての化合物（システインベースのリポペプチド）および組成物 |
| AU2013202310C1 (en) * | 2010-03-29 | 2017-01-05 | Nationwide Children's Hospital, Inc. | Compositions and methods for the removal of biofilms |
| WO2011123396A1 (en) * | 2010-03-29 | 2011-10-06 | University Of Southern California | Compositions and methods for the removal of biofilms |
| AU2011268507B2 (en) | 2010-06-25 | 2014-08-14 | Novartis Ag | Combinations of meningococcal factor H binding proteins |
| AU2011299025B2 (en) | 2010-09-09 | 2015-07-09 | Nationwide Children's Hospital, Inc. | Compositions and methods for the removal of biofilms |
| GB201015132D0 (en) | 2010-09-10 | 2010-10-27 | Univ Bristol | Vaccine composition |
| AU2011300418B2 (en) * | 2010-09-10 | 2016-05-12 | Glaxosmithkline Biologicals Sa | Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom |
| CN103228787B (zh) * | 2010-09-28 | 2017-06-23 | 阿贝拉生物科学公司 | 用于分泌性蛋白表达的融合蛋白 |
| WO2012054879A1 (en) * | 2010-10-22 | 2012-04-26 | Duke University | Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia |
| WO2012153302A1 (en) | 2011-05-12 | 2012-11-15 | Novartis Ag | Antipyretics to enhance tolerability of vesicle-based vaccines |
| CA2840096C (en) | 2011-07-07 | 2021-07-06 | Bas VAN DE WATERBEEMD | A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium |
| JP2015505309A (ja) | 2011-12-29 | 2015-02-19 | ノバルティス アーゲー | 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ |
| MX2014008988A (es) | 2012-02-02 | 2014-08-27 | Novartis Ag | Promotores para aumento de expresion de proteinas en meningococo. |
| JP5698693B2 (ja) * | 2012-03-13 | 2015-04-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 髄膜炎菌特異的抗血清に対する血清殺菌アッセイ |
| US10376573B2 (en) | 2012-06-14 | 2019-08-13 | Glaxosmithkline Biologicals Sa | Vaccines for serogroup X meningococcus |
| RU2015106930A (ru) | 2012-09-06 | 2016-10-20 | Новартис Аг | Комбинированные вакцины с менингококком серогруппы в и к/д/с |
| RU2662970C2 (ru) | 2012-09-18 | 2018-07-31 | Новартис Аг | Везикулы наружной мембраны |
| US20160120818A1 (en) | 2013-02-07 | 2016-05-05 | Glaxosmithline Biological Sa | Pharmaceutical compositions comprising vesicles |
| WO2014138290A1 (en) * | 2013-03-05 | 2014-09-12 | Trudeau Institute, Inc. | Compositions and methods for treating bacterial infections |
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| US9745366B2 (en) | 2013-09-23 | 2017-08-29 | University Of Southern California | Compositions and methods for the prevention of microbial infections |
| US10233234B2 (en) | 2014-01-13 | 2019-03-19 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
| US11248040B2 (en) | 2013-09-26 | 2022-02-15 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
| CA2940447C (en) | 2014-02-28 | 2023-07-11 | Glaxosmithkline Biologicals Sa | Modified meningococcal fhbp polypeptides |
| WO2016091902A1 (en) * | 2014-12-09 | 2016-06-16 | Sanofi Pasteur | Compositions comprising n. meningitidis proteins |
| US11066453B2 (en) | 2015-05-18 | 2021-07-20 | Biomvis Srl | Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof |
| HK1255383A1 (zh) | 2015-07-31 | 2019-08-16 | The Research Institute At Nationwide Children's Hospital | 去除生物膜的肽及抗體 |
| WO2017066719A2 (en) | 2015-10-14 | 2017-04-20 | Research Institute At Nationwide Children's Hospital | Hu specific interfering agents |
| KR101825439B1 (ko) * | 2016-04-15 | 2018-02-05 | 배재대학교 산학협력단 | 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법 |
| WO2018129092A1 (en) | 2017-01-04 | 2018-07-12 | Research Institute At Nationwide Children's Hospital | Antibody fragments for the treatment of biofilm-related disorders |
| EP3565589A1 (en) | 2017-01-04 | 2019-11-13 | Research Institute at Nationwide Children's Hospital | Dnabii vaccines and antibodies with enhanced activity |
| EP3595445B1 (en) | 2017-03-15 | 2024-09-04 | The Research Institute at Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
| EP3607967A1 (en) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
| EP3860718A4 (en) | 2018-10-05 | 2022-08-31 | Research Institute at Nationwide Children's Hospital | HMGB1 PROTEIN DERIVATIVES FOR BIOFILM REMOVAL |
| AU2019376832B2 (en) * | 2018-11-06 | 2024-01-25 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| US12005110B2 (en) | 2019-02-14 | 2024-06-11 | University Of Florida Research Foundation, Incorporated | Honeybee commensal Snodgrassella alvi vaccine against pathogenic Neisseriaceae |
| FR3099160B1 (fr) * | 2019-07-23 | 2022-05-06 | Univ Grenoble Alpes | Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant |
| WO2023097652A1 (en) * | 2021-12-03 | 2023-06-08 | National Center For Nanoscience And Technology | An engineered cell and application thereof |
| GB202203250D0 (en) | 2022-03-09 | 2022-04-20 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| WO2025077793A1 (zh) * | 2023-10-10 | 2025-04-17 | 康希诺生物股份公司 | 一种抗脑膜炎球菌的免疫组合物及其用途 |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239746A (en) * | 1973-06-30 | 1980-12-16 | Dezso Istvan Bartos | Complement fixation test employing reactants in a disposable package |
| DE2744721A1 (de) | 1977-10-05 | 1979-04-19 | Veba Chemie Ag | Pulverfoermige ueberzugsmittel und deren anwendung |
| DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
| EP0027888B1 (en) | 1979-09-21 | 1986-04-16 | Hitachi, Ltd. | Semiconductor switch |
| US4271147A (en) * | 1980-01-10 | 1981-06-02 | Behringwerke Aktiengesellschaft | Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
| US20020146764A1 (en) * | 1985-03-28 | 2002-10-10 | Chiron Corporation | Expression using fused genes providing for protein product |
| IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| DE3622221A1 (de) * | 1986-07-02 | 1988-01-14 | Max Planck Gesellschaft | Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen |
| US5173294A (en) | 1986-11-18 | 1992-12-22 | Research Foundation Of State University Of New York | Dna probe for the identification of haemophilus influenzae |
| RU2023448C1 (ru) | 1987-07-30 | 1994-11-30 | Сентро Насьональ Де Биопрепарадос | Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в |
| HUT58804A (en) | 1988-12-16 | 1992-03-30 | James Cleland Paton | Process for producing pneumolysine mutants and pneumococcus vaccines |
| US7118757B1 (en) * | 1988-12-19 | 2006-10-10 | Wyeth Holdings Corporation | Meningococcal class 1 outer-membrane protein vaccine |
| CU22302A1 (es) * | 1990-09-07 | 1995-01-31 | Cigb | Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales |
| JP3329452B2 (ja) | 1990-07-16 | 2002-09-30 | ザ ユニバーシティー オブ ノースカロライナ | 溶血素群毒素に関するＮ．ｍｅｎｉｎｇｉｔｉｄｉｓ由来抗原性鉄抑制蛋白質 |
| DE4023721A1 (de) | 1990-07-26 | 1992-01-30 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von vakzinen und ihre verwendung |
| US5912336A (en) | 1990-08-23 | 1999-06-15 | University Of North Carolina At Chapel Hill | Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis |
| ES2329979T3 (es) | 1990-08-23 | 2009-12-03 | The University Of North Carolina At Chapel Hill | Proteinas de union de transferencia de neisseria gonorrhoeae y neisseria meningitis. su uso como vacuna. |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| US5652211A (en) | 1991-02-11 | 1997-07-29 | Biosynth S.R.L. | Peptides for neutralizing the toxicity of Lipid A |
| US5371186A (en) | 1991-02-11 | 1994-12-06 | Biosynth S.R.L. | Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock |
| US6592876B1 (en) | 1993-04-20 | 2003-07-15 | Uab Research Foundation | Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products |
| US5476929A (en) | 1991-02-15 | 1995-12-19 | Uab Research Foundation | Structural gene of pneumococcal protein |
| AU1749292A (en) * | 1991-03-14 | 1992-10-21 | Imclone Systems Incorporated | Recombinant hybrid porin epitopes |
| US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
| FR2682041B1 (fr) | 1991-10-03 | 1994-01-14 | Pasteur Merieux Serums Vaccins | Vaccin contre les infections a neisseria meningitidis. |
| JPH07503982A (ja) | 1992-01-13 | 1995-04-27 | アクゾ ノーベル ナムローゼ フェンノートシャップ | エンジニアリングプラスチックを伴うゴムの架橋 |
| KR950700081A (ko) | 1992-02-11 | 1995-01-16 | W 로우 죤 | 이중 캐리어 면역원성 구성물 |
| FR2692592B1 (fr) * | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
| EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| NL9201716A (nl) * | 1992-10-02 | 1994-05-02 | Nederlanden Staat | Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat. |
| GB9224584D0 (en) | 1992-11-23 | 1993-01-13 | Connaught Lab | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases |
| WO1994026304A1 (en) | 1993-05-18 | 1994-11-24 | Ohio State Research Foundation | Otitis media vaccine |
| US5439808A (en) * | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
| US6358727B1 (en) | 1993-11-08 | 2002-03-19 | Aventis Pasteur Limited | Haemophilus transferrin receptor genes |
| US6361779B1 (en) | 1993-11-08 | 2002-03-26 | Aventis Pasteur Limited | Transferrin receptor genes |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US5565204A (en) | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
| US5545553A (en) | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
| IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| US6287574B1 (en) * | 1995-03-17 | 2001-09-11 | Biochem Pharma Inc. | Proteinase K resistant surface protein of neisseria meningitidis |
| US6265567B1 (en) | 1995-04-07 | 2001-07-24 | University Of North Carolina At Chapel Hill | Isolated FrpB nucleic acid molecule |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
| US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
| US6007838A (en) | 1995-06-07 | 1999-12-28 | The United States Of America As Represented By The Secretary Of The Army | Process for making liposome preparation |
| WO1996040928A1 (en) | 1995-06-07 | 1996-12-19 | Biochem Vaccines Inc. | Streptococcal heat shock proteins members of the hsp70 family |
| GB9513074D0 (en) | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
| DK0854729T3 (da) * | 1995-09-18 | 2004-07-12 | Id Biomedical Corp Quebec | Forbedrede fremgangsmåder til fremstillingen af ikke-kovalent kompleksdannede og multivalente proteosom-subunit-vacciner |
| US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
| US6090576A (en) | 1996-03-08 | 2000-07-18 | Connaught Laboratories Limited | DNA encoding a transferrin receptor of Moraxella |
| US6440701B1 (en) | 1996-03-08 | 2002-08-27 | Aventis Pasteur Limited | Transferrin receptor genes of Moraxella |
| ATE323721T1 (de) | 1996-05-01 | 2006-05-15 | Univ Rockefeller | Cholin-bindendes protein, welches als gegen pneumokokken gerichtetes vakzin verwendet wird |
| US7341727B1 (en) | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
| FR2751000B1 (fr) | 1996-07-12 | 1998-10-30 | Inst Nat Sante Rech Med | Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques |
| US5882896A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | M protein |
| US5882871A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | Saliva binding protein |
| WO1998018931A2 (en) | 1996-10-31 | 1998-05-07 | Human Genome Sciences, Inc. | Streptococcus pneumoniae polynucleotides and sequences |
| JP2001502925A (ja) | 1997-06-03 | 2001-03-06 | コノート ラボラトリーズ リミテッド | モラクセラのラクトフェリン受容体遺伝子 |
| JP2001510031A (ja) | 1997-07-21 | 2001-07-31 | ノース・アメリカン・ヴァクシン・インコーポレーテッド | ワクチンとしての修飾された免疫原ニューモリシン組成物 |
| AU4773697A (en) | 1997-07-31 | 1999-02-22 | Wilo Gmbh | Latent heat storage device for use in a vehicle |
| AU744733B2 (en) | 1997-08-15 | 2002-02-28 | Technology Foundation (Technologiestichting Stw) | Neisseria lactoferrin binding protein |
| GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| US6914131B1 (en) * | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
| GB9726398D0 (en) * | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
| SG152917A1 (en) * | 1998-01-14 | 2009-06-29 | Chiron Srl | Neisseria meningitidis antigens |
| CA2264970A1 (en) | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria |
| ES2343492T3 (es) | 1998-04-07 | 2010-08-02 | Medimmune, Llc | Derivados de proteinas neumococicas de union a colina para vacunas. |
| GB9808734D0 (en) | 1998-04-23 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| GB9808866D0 (en) * | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| US20070026021A1 (en) * | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
| EP2261341A3 (en) * | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| GB9809683D0 (en) | 1998-05-06 | 1998-07-01 | Smithkline Beecham Biolog | Novel compounds |
| GB9810276D0 (en) | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
| GB9810285D0 (en) | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
| GB9811260D0 (en) | 1998-05-26 | 1998-07-22 | Smithkline Beecham Biolog | Novel compounds |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| PL198031B1 (pl) | 1998-06-03 | 2008-05-30 | Smithkline Beecham Biolog | Wyizolowany polipeptyd, immunogenny fragment polipeptydu, wyizolowany polinukleotyd, wektor ekspresyjny lub zrekombinowany żywy mikroorganizm, komórka gospodarza, sposób wytwarzania polipeptydu lub immunogennego fragmentu polipeptydu, sposób ekspresji polinukleotydu, kompozycja szczepionki, przeciwciało immunospecyficzne, sposób diagnozowania zakażenia Moraxella catarrhalis, zastosowanie kompozycji, oraz kompozycja terapeutyczna przydatna do leczenia ludzi z Moraxella catarrhalis |
| GB9812163D0 (en) | 1998-06-05 | 1998-08-05 | Smithkline Beecham Biolog | Novel compounds |
| GB9812440D0 (en) | 1998-06-09 | 1998-08-05 | Smithkline Beecham Biolog | Novel compounds |
| GB9814902D0 (en) | 1998-07-10 | 1998-09-09 | Univ Nottingham | Screening of neisserial vaccine candidates against pathogenic neisseria |
| US6951652B2 (en) | 1998-07-29 | 2005-10-04 | Biosynth S.R.L. | Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases |
| GB9818004D0 (en) * | 1998-08-18 | 1998-10-14 | Smithkline Beecham Biolog | Novel compounds |
| GB9820003D0 (en) | 1998-09-14 | 1998-11-04 | Smithkline Beecham Biolog | Novel compounds |
| GB9820002D0 (en) | 1998-09-14 | 1998-11-04 | Smithkline Beecham Biolog | Novel compounds |
| CN1338005A (zh) * | 1998-10-09 | 2002-02-27 | 希龙公司 | 奈瑟球菌基因组序列及其用途 |
| ATE301715T1 (de) | 1998-10-16 | 2005-08-15 | Fraunhofer Ges Forschung | Durch molekulares pathogenicid vermittelte krankheitsresistenz in pflanzen |
| US6610306B2 (en) * | 1998-10-22 | 2003-08-26 | The University Of Montana | OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof |
| EP1123403A1 (en) | 1998-10-22 | 2001-08-16 | The University Of Montana | OMP85 PROTEINS OF $i(NEISSERIA GONORRHOEAE) AND $i(NEISSERIA MENINGITIDIS), COMPOSITIONS CONTAINING SAME AND METHODS OF USE THEREOF |
| GB9823978D0 (en) * | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
| US20030215469A1 (en) * | 1998-11-02 | 2003-11-20 | Microbiological Research Authority | Multicomponent meningococcal vaccine |
| DK1127137T4 (da) | 1998-11-03 | 2014-02-10 | Nederlanden Staat | LPS med reduceret toksicitet fra genetisk modificerede gram-negative bakterier |
| EP1228217B1 (en) * | 1999-04-30 | 2012-11-21 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
| MXPA01011047A (es) * | 1999-04-30 | 2003-10-14 | Chiron Corp | Secuencias genomicas de neisseria y metodos para su uso. |
| GB9911683D0 (en) * | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| EP1860191A3 (en) * | 1999-05-19 | 2008-02-13 | Novartis Vaccines and Diagnostics S.r.l. | Combination neisserial compositions |
| AU1824101A (en) | 1999-06-18 | 2001-01-09 | Elitra Pharmaceuticals, Inc. | Nucleotide sequences of moraxella catarrhalis genome |
| GB2351515B (en) | 1999-06-29 | 2002-09-11 | Pandrol Ltd | Adjustable railway rail fastening assembly and methods for use therewith |
| GB9917977D0 (en) | 1999-07-30 | 1999-09-29 | Smithkline Beecham Biolog | Novel compounds |
| GB9918038D0 (en) | 1999-07-30 | 1999-09-29 | Smithkline Beecham Biolog | Novel compounds |
| GB9918208D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Novel compounds |
| GB9918302D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Novel compounds |
| GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| US6531131B1 (en) * | 1999-08-10 | 2003-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for Neisseria meningitidis |
| AUPQ275799A0 (en) * | 1999-09-10 | 1999-10-07 | Luminis Pty Limited | Recombinant bacterium expressing an oligosaccharide receptor mimic |
| DE60044005D1 (de) | 1999-11-29 | 2010-04-22 | Novartis Vaccines & Diagnostic | 85 kDa Antigen von Neisseria |
| EP2275129A3 (en) * | 2000-01-17 | 2013-11-06 | Novartis Vaccines and Diagnostics S.r.l. | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
| IL150822A0 (en) * | 2000-01-25 | 2003-02-12 | Univ Queensland | PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA |
| CN101139590B (zh) * | 2000-02-28 | 2012-07-18 | 启龙股份公司 | 奈瑟球菌蛋白质的杂交表达 |
| GB0007432D0 (en) * | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| GB0011108D0 (en) * | 2000-05-08 | 2000-06-28 | Microscience Ltd | Virulence gene and protein and their use |
| ES2519440T3 (es) * | 2000-07-27 | 2014-11-07 | Children's Hospital & Research Center At Oakland | Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis |
| GB0103424D0 (en) * | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| GB0108024D0 (en) * | 2001-03-30 | 2001-05-23 | Chiron Spa | Bacterial toxins |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| WO2003009869A1 (en) | 2001-07-26 | 2003-02-06 | Chiron Srl. | Vaccines comprising aluminium adjuvants and histidine |
| GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| MXPA04000653A (es) * | 2001-07-27 | 2004-11-22 | Chiron Srl | Adhesinas de meningococcus nada, app y orf 40. |
| CN100354297C (zh) * | 2001-10-03 | 2007-12-12 | 希龙公司 | 辅助的脑膜炎球菌组合物 |
| DK2255826T3 (en) * | 2002-08-02 | 2016-06-20 | Glaxosmithkline Biologicals Sa | Neisserial vaccine compositions comprising a combination of antigens. |
| DE60335477D1 (de) * | 2002-10-11 | 2011-02-03 | Novartis Vaccines & Diagnostic | Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien |
| PT2172213E (pt) * | 2003-01-30 | 2013-06-03 | Novartis Ag | Vacinas injetáveis contra múltiplos serogrupos meningocócicos |
| GB0315021D0 (en) * | 2003-06-26 | 2003-07-30 | Chiron Srl | Immunogenic gonococcal compositions |
| GB0323103D0 (en) * | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| ATE506963T1 (de) * | 2003-10-02 | 2011-05-15 | Novartis Vaccines & Diagnostic | Kombinationsimpfstoffe gegen meningitis |
| GB0408977D0 (en) * | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| GB0409748D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Lactoferrin cleavage |
| WO2008001224A2 (en) * | 2006-06-29 | 2008-01-03 | Novartis Ag | Polypeptides from neisseria meningitidis |
-
2003
- 2003-07-31 DK DK10177890.0T patent/DK2255826T3/en active
- 2003-07-31 SI SI200332262T patent/SI1524993T1/sl unknown
- 2003-07-31 NZ NZ574530A patent/NZ574530A/en not_active IP Right Cessation
- 2003-07-31 JP JP2005506113A patent/JP2006500963A/ja active Pending
- 2003-07-31 US US10/523,117 patent/US20060240045A1/en not_active Abandoned
- 2003-07-31 NZ NZ537904A patent/NZ537904A/en not_active IP Right Cessation
- 2003-07-31 US US10/523,044 patent/US7838014B2/en not_active Expired - Fee Related
- 2003-07-31 AU AU2003260357A patent/AU2003260357B2/en not_active Ceased
- 2003-07-31 JP JP2005506112A patent/JP4740738B2/ja not_active Expired - Fee Related
- 2003-07-31 WO PCT/EP2003/008569 patent/WO2004015099A2/en not_active Ceased
- 2003-07-31 KR KR1020117004904A patent/KR101237329B1/ko not_active Expired - Fee Related
- 2003-07-31 CA CA002493977A patent/CA2493977A1/en not_active Abandoned
- 2003-07-31 EP EP12157807.4A patent/EP2481419A3/en not_active Withdrawn
- 2003-07-31 PT PT37841533T patent/PT1524993E/pt unknown
- 2003-07-31 DE DE20321889U patent/DE20321889U1/de not_active Expired - Lifetime
- 2003-07-31 KR KR1020127002482A patent/KR101239242B1/ko not_active Expired - Fee Related
- 2003-07-31 AU AU2003253375A patent/AU2003253375B2/en not_active Ceased
- 2003-07-31 HU HUE10177890A patent/HUE029200T2/en unknown
- 2003-07-31 NZ NZ587398A patent/NZ587398A/en not_active IP Right Cessation
- 2003-07-31 CA CA002489030A patent/CA2489030A1/en not_active Abandoned
- 2003-07-31 AU AU2003250204A patent/AU2003250204B8/en not_active Ceased
- 2003-07-31 WO PCT/EP2003/008571 patent/WO2004014418A2/en not_active Ceased
- 2003-07-31 EP EP03784152.5A patent/EP1524992B1/en not_active Expired - Lifetime
- 2003-07-31 ES ES03784152.5T patent/ES2537737T3/es not_active Expired - Lifetime
- 2003-07-31 PT PT101778900T patent/PT2255826E/pt unknown
- 2003-07-31 EP EP08153843A patent/EP1961427A3/en not_active Withdrawn
- 2003-07-31 SI SI200332485A patent/SI2255826T1/sl unknown
- 2003-07-31 AU AU2003269864A patent/AU2003269864A1/en not_active Abandoned
- 2003-07-31 JP JP2005506114A patent/JP2006506467A/ja active Pending
- 2003-07-31 EP EP10177891A patent/EP2258386A3/en not_active Withdrawn
- 2003-07-31 PL PL03375408A patent/PL375408A1/xx not_active Application Discontinuation
- 2003-07-31 EP EP10177892A patent/EP2258387A3/en not_active Withdrawn
- 2003-07-31 PL PL399492A patent/PL399492A1/pl not_active Application Discontinuation
- 2003-07-31 EP EP10177887A patent/EP2258385A3/en not_active Withdrawn
- 2003-07-31 CN CNA038184540A patent/CN1671413A/zh active Pending
- 2003-07-31 ES ES10177890.0T patent/ES2575014T3/es not_active Expired - Lifetime
- 2003-07-31 KR KR1020057001941A patent/KR101140033B1/ko not_active Expired - Fee Related
- 2003-07-31 CA CA2493124A patent/CA2493124C/en not_active Expired - Fee Related
- 2003-07-31 EP EP03784153A patent/EP1524993B1/en not_active Revoked
- 2003-07-31 TW TW092121011A patent/TWI360424B/zh not_active IP Right Cessation
- 2003-07-31 DK DK03784153.3T patent/DK1524993T3/da active
- 2003-07-31 EP EP10177890.0A patent/EP2255826B1/en not_active Expired - Lifetime
- 2003-07-31 EP EP03750408A patent/EP1524990A2/en not_active Withdrawn
- 2003-07-31 PL PL03375382A patent/PL375382A1/xx not_active IP Right Cessation
- 2003-07-31 ES ES03784153T patent/ES2408251T3/es not_active Expired - Lifetime
- 2003-07-31 MX MXPA05001349A patent/MXPA05001349A/es active IP Right Grant
- 2003-07-31 CN CN038186489A patent/CN1674933B/zh not_active Expired - Fee Related
- 2003-07-31 PL PL375407A patent/PL216662B1/pl unknown
- 2003-07-31 WO PCT/EP2003/008568 patent/WO2004014417A2/en not_active Ceased
- 2003-07-31 US US10/523,114 patent/US20060034854A1/en not_active Abandoned
- 2003-07-31 MY MYPI20032904A patent/MY149591A/en unknown
- 2003-07-31 CA CA002493092A patent/CA2493092A1/en not_active Abandoned
- 2003-07-31 US US10/523,055 patent/US20060057160A1/en not_active Abandoned
- 2003-07-31 WO PCT/EP2003/008567 patent/WO2004014419A1/en not_active Ceased
- 2003-07-31 EP EP10177881A patent/EP2258384A3/en not_active Withdrawn
- 2003-07-31 KR KR1020087019883A patent/KR101139976B1/ko not_active Expired - Fee Related
- 2003-07-31 EP EP03784151A patent/EP1524991A1/en not_active Withdrawn
- 2003-07-31 DE DE20321890U patent/DE20321890U1/de not_active Expired - Lifetime
- 2003-07-31 MX MXPA05001265A patent/MXPA05001265A/es active IP Right Grant
- 2003-07-31 KR KR1020057001933A patent/KR20050039839A/ko not_active Ceased
- 2003-07-31 KR KR1020057001924A patent/KR20050028051A/ko not_active Withdrawn
- 2003-07-31 NZ NZ537181A patent/NZ537181A/en not_active IP Right Cessation
- 2003-07-31 JP JP2005506111A patent/JP5409986B2/ja not_active Expired - Fee Related
- 2003-07-31 PL PL399214A patent/PL220107B1/pl unknown
- 2003-07-31 MX MXPA05000842A patent/MXPA05000842A/es active IP Right Grant
-
2004
- 2004-12-09 IL IL16566004A patent/IL165660A0/xx unknown
- 2004-12-13 IS IS7593A patent/IS7593A/is unknown
- 2004-12-16 IS IS7601A patent/IS7601A/is unknown
-
2005
- 2005-01-03 NO NO20050010A patent/NO20050010L/no not_active Application Discontinuation
- 2005-01-03 NO NO20050008A patent/NO20050008L/no not_active Application Discontinuation
- 2005-01-20 IL IL166433A patent/IL166433A/en active IP Right Grant
- 2005-01-20 IS IS7658A patent/IS7658A/is unknown
- 2005-01-25 NO NO20050421A patent/NO20050421L/no not_active Application Discontinuation
- 2005-01-28 CO CO05007268A patent/CO5680456A2/es not_active Application Discontinuation
- 2005-01-28 CO CO05007266A patent/CO5680455A2/es not_active Application Discontinuation
- 2005-01-28 CO CO05007265A patent/CO5680454A2/es active IP Right Grant
-
2008
- 2008-06-04 AU AU2008202479A patent/AU2008202479C1/en not_active Ceased
- 2008-12-12 AU AU2008255270A patent/AU2008255270A1/en not_active Abandoned
-
2010
- 2010-10-21 US US12/909,621 patent/US8221770B2/en not_active Expired - Fee Related
- 2010-10-22 JP JP2010237357A patent/JP5414651B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-04 JP JP2011047056A patent/JP2011142916A/ja active Pending
- 2011-05-31 IL IL213264A patent/IL213264A0/en unknown
- 2011-09-29 US US13/248,693 patent/US20120027800A1/en not_active Abandoned
- 2011-11-17 US US13/299,007 patent/US20120064119A1/en not_active Abandoned
- 2011-11-17 US US13/299,041 patent/US20120064120A1/en not_active Abandoned
-
2012
- 2012-02-10 JP JP2012026928A patent/JP5789203B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-31 CY CY20131100435T patent/CY1114243T1/el unknown
- 2013-07-31 LU LU92262C patent/LU92262I2/fr unknown
- 2013-09-05 CY CY2013036C patent/CY2013036I1/el unknown
-
2015
- 2015-09-03 US US14/844,989 patent/US20160082097A1/en not_active Abandoned
-
2016
- 2016-06-15 CY CY20161100532T patent/CY1117643T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2255826T3 (en) | Neisserial vaccine compositions comprising a combination of antigens. | |
| ZA200500927B (en) | Neisserial vaccine compositions comprising a combination of antigens | |
| HK1144909A (en) | Neisseria vaccine composition | |
| HK1077014B (en) | Neisserial vaccine compositions comprising a combination of antigens | |
| HK1144914A (en) | Neisseria vaccine composition | |
| HK1144913A (en) | Neisseria vaccine composition | |
| HK1115812A (en) | Neisserial vaccine compositions comprising a combination of antigens | |
| HK1144777A (en) | Neisserial vaccine compositions comprising a combination of antigens | |
| HK1144910A (en) | Neisseria vaccine composition | |
| AU2013201086A8 (en) | Neisserial vaccine compositions comprising a combination of antigens | |
| NZ552686A (en) | Neisserial vaccine compositions comprising a combination of antigens |